1307P - Clinical characteristics and therapeutic sequences of KRAS G12C advanced non-small cell lung cancer (aNSCLC) patients (pts) treated by sotorasib in the French post-marketing authorization early access (post-MA EA)

Conclusions

Between 06/2022 and 10/2023, more than 1,600 pts were treated by sotorasib through French post-MA EA, highlighting the unmet therapeutic need. Clinical characteristics are consistent with those of CodeBreaK 200 trial pts. Interestingly, in post-MA EA, more pts received sotorasib in 2L, reflecting conditional marketing authorization granted in Europe, mostly after CT+IO in 1L.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Amgen.

Funding

Amgen.

Disclosure

J. Cadranel: Financial Interests, Personal, Advisory Board, Participation to boards: AMGEN, Jansen, AZ, MSD, Takeda, Daichi; Financial Interests, Institutional, Other, prospective: AbbVie; Financial Interests, Institutional, Advisory Board, Participation to boards: Sanofi, Novartis; Financial Interests, Personal, Invited Speaker, Participation to boards: BI; Financial Interests, Personal, Advisory Board, Participation to Boards: Pfizer; Financial Interests, Institutional, Research Grant, Support to academic trial: Pfizer; Financial Interests, Institutional, Research Grant, Preclinical research: Sanofi; Financial Interests, Institutional, Research Grant, Translational research: AbbVie; Non-Financial Interests, Principal Investigator, Trials: BMS, Jansen, Sanofi, AMGEN, Novartis, Pfizer, Daichi, BI, Takeda, AbbVie, AZ. H. Curcio: Financial Interests, Personal, Speaker, Consultant, Advisor: Viatris. Y. Oulkhouir: Financial Interests, Personal, Invited Speaker: Amgen. S. Couraud: Financial Interests, Personal and Institutional, Member of Board of Directors: Adene; Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: Amgen, Boehringer; Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca, BMS, Takeda; Financial Interests, Institutional, Funding: BD, Celgene, Chugai, Lilly; Financial Interests, Personal, Speaker, Consultant, Advisor: Health Event; Financial Interests, Personal and Institutional, Sponsor/Funding: Janssen, MSD, Novartis, Pfizer, Sanofi; Financial Interests, Personal, Sponsor/Funding: MaaT Pharma, Pierre Fabre, SNCF; Financial Interests, Institutional, Sponsor/Funding: Roche, Transdiag, Volition. J. Mazieres: Financial Interests, Personal, Speaker, Consultant, Advisor: Roche, AstraZeneca, Pierre Fabre, Takeda, BMS, MSD, Pfizer, Jiangsu Hengruii, Blueprint, Daiichi Sankyo, Novartis, Amgen; Financial Interests, Personal and Institutional, Research Grant: Roche, AstraZeneca, Pierre Fabre, BMS, Illumina. A. Métivier: Financial Interests, Personal, Speaker, Consultant, Advisor: Takeda, MSD, BMS, Novartis, Pfizer. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Family member is an employee: AstraZeneca. M. Wislez: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, AstraZeneca, BMS, F. Hoffman La Roche, Janssen, MSD Oncology, Lilly, Merck Serono, Novartis, Pfizer, Takeda, Sanofi, Leopharma; Non-Financial Interests, Personal, Other: Transgene. F. Guisier: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, MSD, Roche, Sanofi, Janssen, Pfizer, Takeda; Financial Interests, Institutional, Research Grant: Pfizer, Roche, Takeda. X. Quantin: Financial Interests, Institutional, Invited Speaker: Sanofi; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Other, Educational support: AstraZeneca. C. Naltet: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, MSD, Pfizer, BMS, Sanofi, Janssen, Amgen, Takeda; Non-Financial Interests, Personal, Sponsor/Funding: Roche. B. Roch: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, AstraZeneca, Amgen, Roche, Chugai, Lilly, Takeda; Non-Financial Interests, Personal, Non remunerated activity: MSD; Non-Financial Interests, Non remunerated activity: Novartis. L. Greillier: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, BMS, MSD, Novartis, Sanofi, Takeda, Roche; Financial Interests, Personal, Invited Speaker: Lilly, Pfizer; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, BMS, MSD, Novartis, Takeda, Pfizer, PharmaMar; Financial Interests, Institutional, Coordinating PI: Sanofi; Financial Interests, Personal, Local PI: Roche. C. Clément: Financial Interests, Personal, Full or part-time Employment: Amgen. L. De Gunten: Financial Interests, Personal, Full or part-time Employment: Amgen. V. Gounant: Financial Interests, Personal, Advisory Role: Janssen, Sanofi, Takeda, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca Pharmaceuticals LP; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb Co. All other authors have declared no conflicts of interest.